Latest Content

Brian Smith, PharmD, explains how direct-to-consumer GLP-1 pathways broaden initial access but endanger long-term patient adherence.

Pharmacists face burnout and financial strain as PBMs take big cuts, prompting urgent calls for reform to protect patient care and community pharmacies.

What pharmacy technicians say would actually make them feel seen on World Pharmacy Technician Day, and the other 364 days of the year.

The analysis is not a head-to-head trial, and the weight loss gap reached statistical significance under 1 of 2 estimands.

A 1.6-million-birth analysis finds that adoption of a 2016 trial's antibiotic protocol climbed sharply in US hospitals, with a drop in infection rates.

New findings suggest semaglutide's benefits may extend well beyond diabetes and weight loss and into airway disease and mood disorders.

First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.

With the inherent value medications provide in the greater health care system, Jennifer Hammons, PharmD, DrPH, argues that rural pharmacies deserve the proper recognition.

A claims analysis of 2031 patients aged 10 to 17 years found that nutrition counseling was infrequent and often began months after treatment started.

Researchers compared vaccine coadministration with single-dose, sequential vaccination for the RSVPreF3 OA vaccine formulation in adults.

A study of women aged 50 to 69 years found that thrombotic risk varied by route of administration, estradiol dose, and duration of use.

Despite technology fostering a new generation of health care delivery, experts believe rural health solutions should be sought elsewhere.

Medicaid coverage of obesity-labeled GLP-1 receptor agonists may substitute for, rather than simply add to, diabetes-labeled use, a new study finds.

Researchers outline individual peripheral arterial disease burden as well as the most at-risk patient populations and treatment recommendations.

Availability will vary by state, and a pharmacy professor says cost barriers can keep families from getting vaccinated.

Darren Mensch, PharmD, BCPS, BCACP, provides evidence-based nuance regarding the emergence of mRNA vaccine technology and health care’s understanding of it.

Study findings tie continuous glucose monitoring measures to elevated cardiovascular risk in adults without diabetes.

The once daily tablet is expected to reach US patients in October 2026.

The label expansion adds patients 12 years of age and older to the once daily alopecia areata indication.

Pharmacist and public health expert Jennifer Hammons, PharmD, DrPH, discusses pharmacy as essential infrastructure amid rural pharmacies persistently being overlooked.

An American Heart Association scientific statement shows earlier risk factors and social barriers driving cardiovascular disparities in Hispanic adults.

In an exploration of 2 distinct timeframes in the 21st century, researchers examine the use and concurrent use of medication types among elderly US adults.

The investigational anti–IL-33 antibody lowered exacerbation rates across all blood eosinophil levels, a benefit current COPD biologics do not offer.

This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.

A study finds children starting continuous glucose monitoring within a month of diagnosis sustained lower hemoglobin A1C than those who started later.

With obesity, muscle loss, and sleep disorders so prominent in postmenopause, providers are now looking into further expansion of GLP-1 use.

Menopause status and symptoms are inconsistently captured in electronic health records, leaving a gap in care for patients.

As midterm elections approach, the pharmacy industry is backing one of its most meaningful bills yet while the current congressional session wanes.

Data found reduced cardiovascular risk with hormone therapy, particularly among Black women and those starting treatment within 10 years of menopause.

Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.

Pennsylvania has become the center of the outbreak as cases exceed 775 alongside conflicting mortality reports.